September 2006

Contents

Editorial

• Volume 7 Number 9 September 2006

Conference reports

• XVI International AIDS Conference, Toronto, Canada. 13-18 August 2006

• Enough is enough: South African activists demand: fire Manto

• Treatment access: more optimistic results from scale up programmes

• Integrase inhibitor MK-0518: early results show greater early potency than efavirenz

• Maraviroc results in R5/X4 mixed/dual tropic patients: unexpected safety data shows possible immunolocical effect

• Vicriviroc 24-week results in triple-class experienced R5-tropic patients

• Etravirine (TMC-125) associated with -1 log viral load reduction at 48-weeks results in treatment experienced patients

• Three-class experienced patients experience 1 log viral load reduction using monoclonal antibody TNX-355

• New data on darunavir (TMC-114)

• Lopinavir/r monotherapy: less potent than triple therapy with higher risk of resistance

• Atazanavir/r monotherapy and CNS penetration

• Fosamprenavir/r is non-inferior to Kaletra in treatment naive patients

• Tenofovir/FTC maintains greater virological response and reduced lipoatrophy compared to AZT/3TC after 96 weeks

• Children face a serious service delivery gap: paediatric studies in Toronto

• Bioavailability study results for new paediatric tablets for oral suspension, and caution against splitting adult doses

• Pharmacokinetic and virological evaluations after stopping NNRTIs in children: a substudy of the PENTA 11 (TICCH) Trial

• 3TC/abacavir maintains virological superiority over AZT/3TC and AZT/abacavir beyond 5 years in children

• French study raises importance of early screening for anal cancer in HIV-positive people

• Prognostic index for risk of progression of Kaposi’s Sarcoma

• Tenofovir did not increase the incidence nephrotoxicity in limited numbers of HIV-positive patients using chemotherapy or HCV-coinfeced patients using ribavirin

• Selected abstracts from Track A presentations at Toronto

• Use of complementary alternative medicine that could interact with ARV treatment reported by 20% patients in the UK

• Poor scientific or medical knowledge is a factor in increase in criminal charges for HIV transmission in the UK

• Treatment access and community responses: online webcasts and debates

Antiretrovirals

• Antiretroviral effect of foscarnet in patients with multiple drug resistance in late stage HIV disease

Treatment access

• Patent oppositions filed on three essential drugs

Guidelines

• WHO guidelines for ARV treatment in resource limited settings (2006)

On the web

• AIDS issue of the British medical journal The Lancet online

• TAG pipeline drugs report: July 2006

• OSI/TAG report on civil society involvement in TB/HIV

• Tuberculosis R&D Investments: A Preliminary Assessment

• Resource for HIV-positive travellers: HIV/AIDS regulations

PDFs

• Volume 7 Number 9 September 2006 PDF